Pseudoevidence-based medicine: What it is, and what to do about it

Clinical Governance

Volumn 12, Issue 1, 2007, Pages 42-52

  Smith, Wally R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Clinical governance; Evidence based practice; Medical ethics; Pharmaceuticals industry; Quality improvement; Research methods

Indexed keywords

DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; MALPRACTICE; MEDICAL ETHICS; MEDICAL PRACTICE; PATIENT CARE; PRIORITY JOURNAL; PROFESSIONALISM; QUALITY CONTROL; REVIEW;

EID: 33846445647     PISSN: 14777274     EISSN: None     Source Type: Journal    
DOI: 10.1108/14777270710725409     Document Type: Review

References (41)

1. ABIM Foundation, ACP-ASIM Foundation and European Federation of Internal Medicine (2002a), "Medical professionalism in the new millennium: A medical statute", Rev Clin Esp., Vol. 202 No. 8, pp. 451-4.
2. ABIM Foundation, ACP-ASIM Foundation and European Federation of Internal Medicine (2002b), "Medical professionalism in the new millennium: A physician charter", Obstet Gynecol., Vol. 100 No. 1, pp. 170-2.
3. ABIM Foundation, American Board of Internal Medicine, ACP-ASIM Foundation, American College of Physicians-American Society of Internal Medicine and European Federation of Internal Medicine (2002c), "Medical professionalism in the new millennium: A physician charter", Ann Intern Med., Vol. 136 No. 3, pp. 243-6.
4. ABIM Foundation, ACP-ASIM Foundation and European Federation of Internal Medicine (2003), "Medical professionalism in the new millenium: A physician charter", J Am Coll Surg., Vol. 196 No. 1, pp. 115-8.
5. Angell, M. (2005), The Truth About Drug Companies: How They Deceive Us and What To Do About It, Random House, New York, NY, p. 336.
6. Barbour, V., Butcher, J., Cohen, B. and Yamey, G. (2004), "Prescription for a healthy journal", PLoS Med, Vol. 1, p. e22.
7. Blank, L., Kimball, H., McDonald, W., Merino, J., ABIM Foundation, ACP Foundation and European Federation of Internal Medicine (2003), "Medical professionalism in the new millennium: A physician charter 15 months later", Ann Intern Med, Vol. 138 No. 10, pp. 839-41.
8. Bombardier, C., Laine, L. and Reicin, A. et al. (2000), "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis", N Engl J Med, Vol. 343, pp. 1520-8.
9. Brennan, T.A., Rothman, D.J. and Blank, L. et al. (2006), "Health industry practices that create conflicts of interest: A policy proposal for academic medical centers", JAMA, Vol. 295, pp. 429-33.
10. Campbell, E.G., Weissman, J.S., Moy, E. and Blumenthal, D. (2001), "Status of clinical research in academic health centers: View from the research leadership", JAMA, Vol. 286, pp. 845-6.
11. CBO (1994), "A CBO study: How health care reform affects pharmaceutical research and development", June, Congressional Budget Office, Congress of the United States, available at: www.cbo.gov/ftpdocs/48xx/doc4846/doc31.pdf (accessed 20 November 2006).
12. Cleary, J.D. (1992), "Impact of pharmaceutical sales representatives on physician antibiotic prescribing", J Pharm Tech., Vol. 8, pp. 27-9.
13. DHHS (2003), FDA's Review Process for New Drug Applications: A Management Review, publication no. OEI-01-01-00590, Department of Health and Human Services, Washington, DC.
14. Evidence-Based Care Resource Group (1994a), "Evidence-based care: 1. Setting priorities: How important is the problem?", CMAJ, Vol. 150 No. 8, pp. 1249-54.
15. Evidence-Based Care Resource Group (1994b), "Evidence-based care: 2. Setting guidelines: How should we manage this problem?", CMAJ, Vol. 150 No. 9, pp. 1417-23.
16. Evidence-Based Care Resource Group (1994c), "Evidence-based care: 3. Measuring performance: How are we managing this problem?", CMAJ, Vol. 150 No. 10, pp. 1575-9.
17. Evidence-Based Care Resource Group (1994d), "Evidence-based care: 4. Improving performance: How can we improve the way we manage this problem?", CMAJ, Vol. 150 No. 11, pp. 1793-6.
18. Evidence-Based Medicine Working Group (1992), "Evidence-based medicine: A new approach to teaching the practice of medicine", JAMA, Vol. 268, pp. 2420-5.
19. Guyatt, G.H., Haynes, R.B., Jaeschke, R.Z., Cook, D.J., Green, L., Naylor, C.D., Wilson, M.C. and Richardson, W.S. (2000), "Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group", JAMA, Vol. 284 No. 10, pp. 1290-6.
20. Harlan, D. (1994), "The implications of practice guidelines for physician medical malpractice liability", Physician Executive, May.
21. Horton, R. (2004a), "The dawn of McScience", The New York Review of Books, Vol. 51 No. 4, pp. 7-9.
22. Horton, R. (2004b), "Vioxx, the implosion of Merck, and aftershocks at the FDA", Lancet, Vol. 364, pp. 1995-6.
23. Irwin, R.S., Baumann, M.H. and Bolser, D.C. et al. (2006), "American College of Chest Physicians (ACCP). Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines", Chest, Vol. 129 No. 1, pp. 1S-23S.
24. Kassirer, J.P. (2004), "51", On the Take: How Medicine's Complicity With Big Business Can Endanger Your Health,, Oxford University Press, New York, NY, p. 251.
25. Lancet (2002), "Medical Professionalism Project: Medical professionalism in the new millennium: A physicians' charte", Vol. 359 No. 9305, pp. 520-2.
26. Ma, J., Stafford, R.S., Cockburn, I.M. and Finkelstein, S.N. (2003), "A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998", Clin Ther., Vol. 25 No. 5, pp. 1503-17.
27. Nature (2003), "Secrecy damages the NIH", Vol. 426, p. 739.
28. Orlowski, J.P. and Wateska, L. (1992), "the effects of pharmaceutical firm enticements on physician prescribing patterns", Chest, Vol. 102, pp. 270-3.
29. Plantz, S.H., Kreplick, L.W., Panacek, E.A., Mehta, T., Adler, J. and McNamara, R.M. (1998), "A national survey of board-certified emergency physicians: Quality of care and practice structure issues", Am J Emerg Med., Vol. 16 No. 1, pp. 1-4.
30. Poses, R.M. (2003), "A cautionary tale: The dysfunction of American health care", Eur J Intern Med., Vol. 14 No. 2, pp. 123-30.
31. Poses, R.M., Silverstein, S. and Smith, W.R. (2006), "Academic medical centers and conflicts of interest", JAMA, Vol. 2846-7, pp. 2848-9.
32. Psaty, B.M. and Burke, S.P. (2006), "Protecting the health of the public - Institute of Medicine recommendations on drug safety", N Engl J Med., Vol. 355, pp. 1753-5.
33. Sackett, D.L. and Oxman, A.D. (2003), "HARLOT plc: An amalgamation of the world's two oldest professions", BMJ, Vol. 327 No. 7429, pp. 1442-5.
34. Sherman, S.N., Mrus, J.M., Yi, M.S., Feinberg, J. and Tsevat, J. (2006), "How do patients with HIV/AIDS understand and respond to health value questions?", J Gen Intern Med., December, Suppl. 5, pp. S56-S61.
35. Sigworth, S.K., Nettleman, M.D. and Cohen, G.M. (2001), "Pharmaceutical branding of resident physicians", JAMA, Vol. 286 No. 9, pp. 1024-5.
36. Smith, R. (2005), "Curbing the Influence of the drug industry: A British view", PLoS Med, Vol. 2 No. 9, p. e241.
37. Smith, R. (2005), "Medical journals are an extension of the marketing arm of pharmaceutical companies", PLoS Med, Vol. 2 No. 5, p. e138.
38. Steinbrook, R. (2004), "Conflicts of interest at the NIH - resolving the problem", N Engl J Med, Vol. 351, pp. 955-7.
39. Steinbrook, R. (2005), "Standards of ethics at the National Institutes of Health", N Engl J Med, Vol. 352, pp. 1290-2.
40. Topol, E.J. (2004), "Failing the public health - rofecoxib, Merck and the FDA", N Engl J Med, Vol. 351, pp. 1707-9.
41. Twedt, S. (2003), "The cost of courage: How the tables turn on doctors", Pittsburgh Post-Gazette, 26 October.